Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04074161 · ClinicalTrials.gov registry record · Phase 3
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 338
- Enrollment target
NCT04074161 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 338 participants.
The verdict
NCT04074161, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 338 participants
- Enrollment target
Study Summary
This study will look at participants' body weight from the start to the end of the study. The study will last for about 1½ years. This is to compare the effect on body weight in people taking semaglutide once a week or people taking liraglutide once every day. Participants will either get semaglutide, liraglutide or "dummy" medicine. Which treatment is decided by chance. Participants who receive semaglutide or semaglutide "dummy" medicine will need to take 1 injection once a week. Participants who receive liraglutide or liraglutide "dummy" medicine will need to take 1 injection once daily. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. During the study participants will have talks with study staff about eating healthy food and how to be more physically active. Participants will have 16 clinic visits and 7 phone calls with the study doctor. At 4 of the clinic visits participants cannot eat and drink (water is allowed) for 8 hours before the visit. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.
Interventions
- DRUG Semaglutide
- DRUG Liraglutide
- DRUG Placebo (semaglutide)
- DRUG Placebo (liraglutide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2019-09-11 |
| Est. Completion | 2021-05-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04074161
The ClinicalTrials.gov registry entry for NCT04074161 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 338 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Semaglutide is the first listed.
NCT04074161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04074161 about?
NCT04074161 is a clinical study titled "Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity". This study will look at participants' body weight from the start to the end of the study. The study will last for about 1½ years. This is to compare the effect on body weight in people taking semaglutide once a week or people taking liraglutide once every day. Participants will either get semaglutid...
What is the current status of trial NCT04074161?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 338 participants. The study started on 2019-09-11. Estimated completion is 2021-05-11.
What interventions are being tested in trial NCT04074161?
The interventions under investigation include: Semaglutide (DRUG), Liraglutide (DRUG), Placebo (semaglutide) (DRUG), Placebo (liraglutide) (DRUG).
Who is sponsoring clinical trial NCT04074161?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.